A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-15

Study Completion Date

2017-07-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial to Assess Subjects With Dry Eye Disease.

NCT04971031

Dry Eye

COMPLETED PHASE2

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393

Dry Eye Disease

COMPLETED PHASE3

A Study of RX-10045 in the Treatment of Dry Eye Disease

NCT01675570

Dry Eye Syndrome

COMPLETED PHASE2

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597

Dry Eye Disease

COMPLETED PHASE2

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358

Dry Eye Dry Eye Syndromes

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADX-102 Ophthalmic Solution (0.5%)

Group Type EXPERIMENTAL

ADX-102 Ophthalmic Solution (0.5%)

Intervention Type DRUG

ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.

ADX-102 Ophthalmic Solution (0.1%)

Group Type EXPERIMENTAL

ADX-102 Ophthalmic Solution (0.1%)

Intervention Type DRUG

ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.

ADX-102 Ophthalmic Lipid Solution (0.5%)

Group Type EXPERIMENTAL

ADX-102 Ophthalmic Lipid Solution (0.5%)

Intervention Type DRUG

ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADX-102 Ophthalmic Solution (0.5%)

ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.

Intervention Type DRUG

ADX-102 Ophthalmic Solution (0.1%)

ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.

Intervention Type DRUG

ADX-102 Ophthalmic Lipid Solution (0.5%)

ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age of either gender and any race;
* Have a reported history of dry eye for at least 6 months prior to Visit 1;
* Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;

Exclusion Criteria

* Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
* Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
* Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
* Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
* Have used cyclosporine 0.05% or lifitegrast 5.0% ophthalmic solution within 45 days of Visit 1;
* Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months;
* Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No